Drugs / PBF-1129
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05234307 | Nov 2022 → Dec 2026 expected | non-small cell lung carcinoma | Dwight Owen | Recruiting | No outcome recorded |
| Phase 1 | NCT03274479 | Oct 2018 → May 2024 | — | Palobiofarma SL | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-02-01 | Palo Biofarma, S.L | Regulatory FDA grants Palobiofarma approval to start second anti-cancer study in USA palobiofarma.com ↗
Palobiofarma has received FDA approval to initiate a Phase I clinical trial with the novel adenosine A2b antagonist PBF-1129 in lung cancer patients. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-02-01 | Palo Biofarma, S.L | FDA grants Palobiofarma approval to start second anti-cancer study in USA palobiofarma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBF-1129 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05234307 ↗ |
| Action | Inhibit | “PBF-1129, an oral, selective A2B adenosine receptor (A2BAR) antagonist” PMID 41335275 ↗ Dec 2025 |
| Modality | Monoclonal antibody | “Immunotherapy with monoclonal antibodies, such as PBF-1129 and nivolumab” NCT05234307 ↗ |
| Route | Oral | “PBF-1129 once a day by oral administration” NCT03274479 ↗ |